Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Aggressive systemic mastocytosis (ASM) is a severe and rare form of systemic mastocytosis (SM) characterized by considerable infiltration of mast cells in different tissues.
Biomarker and diagnostic research for aggressive systemic mastocytosis has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily industry-sponsored.
134 publications have been identified in PubMed for aggressive systemic mastocytosis. Research spans Review / Meta-Analysis (34%), Epidemiology / Natural History (16%), and Case Report / Case Series (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 46 | 34% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 9:39 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about aggressive systemic mastocytosis
Disease patterns and progression |
21 |
16% |
Patient case studies | 16 | 12% |
Laboratory research | 16 | 12% |
Testing and diagnosis research | 13 | 10% |
Clinical study results | 12 | 9% |
New treatment approaches | 7 | 5% |
Other research | 3 | 2% |
Chernak BJ (2026). [PMID: 41518005](https://pubmed.ncbi.nlm.nih.gov/41518005/). *Leuk Lymphoma*. [Review / Meta-Analysis]
Vardanyan S (2026). [PMID: 41943513](https://pubmed.ncbi.nlm.nih.gov/41943513/). *Expert Rev Hematol*. [Other]
Tse KY (2026). [PMID: 42011426](https://pubmed.ncbi.nlm.nih.gov/42011426/). *J Allergy Clin Immunol Glob*. [Epidemiology / Natural History]
Rama TA (2026). [PMID: 41801525](https://pubmed.ncbi.nlm.nih.gov/41801525/). *Curr Allergy Asthma Rep*. [Review / Meta-Analysis]
Frost M (2026). [PMID: 41935968](https://pubmed.ncbi.nlm.nih.gov/41935968/). *Pediatr Blood Cancer*. [Other]
Gotlib J (2026). [PMID: 41604606](https://pubmed.ncbi.nlm.nih.gov/41604606/). *Blood advances*. [Gene Therapy / Novel Therapeutics]
Carter MC (2026). [PMID: 41285204](https://pubmed.ncbi.nlm.nih.gov/41285204/). *The journal of allergy and clinical immunology. In practice*. [Review / Meta-Analysis]
Hoermann G (2026). [PMID: 40846032](https://pubmed.ncbi.nlm.nih.gov/40846032/). *The journal of allergy and clinical immunology. In practice*. [Basic Science / Preclinical]
Khot R (2026). [PMID: 41433193](https://pubmed.ncbi.nlm.nih.gov/41433193/). *Radiographics : a review publication of the Radiological Society of North America, Inc*. [Diagnostic / Biomarker]
Fazio M (2026). [PMID: 41677670](https://pubmed.ncbi.nlm.nih.gov/41677670/). *Cells*. [Review / Meta-Analysis]